article Open AccessTop 1% cited

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

Leukemia · 2009 · Vol. 23(5) · pp. 905–911

Ayalew Tefferi✉(Mayo Clinic in Arizona)Animesh Pardanani(Mayo Clinic in Arizona)Ken‐Hong Lim(Mayo Clinic in Arizona)Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center)Terra L. Lasho(Mayo Clinic in Arizona)Jay Patel(Memorial Sloan Kettering Cancer Center)Naseema Gangat(Mayo Clinic in Arizona)Christy M. Finke(Mayo Clinic in Arizona)Susan M. Schwager(Mayo Clinic in Arizona)Ann Mullally(Brigham and Women's Hospital)C. Y. Li(Mayo Clinic in Arizona)Curtis A. Hanson(Mayo Clinic in Arizona)Ruben A. Mesa(Mayo Clinic in Arizona)Olivier Bernard(Université Paris Cité)François Delhommeau(Institut Gustave Roussy)William Vainchenker(Institut Gustave Roussy)D. Gary Gilliland(Dana-Farber Cancer Institute)Ross L. Levine(Memorial Sloan Kettering Cancer Center)

View via DOI Publisher page

Myeloproliferative Neoplasms: Diagnosis and Treatment Chronic Myeloid Leukemia Treatments Kruppel-like factors researchMyelofibrosisEssential thrombocythemiaPolycythemia veraMissense mutationFrameshift mutationInternal medicineMyeloproliferative neoplasmMedicineBone marrowMutation frequency

MeSH terms

AgedAged, 80 and overDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMutationPolycythemia VeraProto-Oncogene ProteinsThrombocythemia, EssentialSurvival RateDioxygenasesJanus Kinase 2Primary Myelofibrosis

Citations

418

FWCI

25.99

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Mutations of polycomb‐associated gene <i>ASXL1</i> in myelodysplastic syndromes and chronic myelomonocytic leukaemia